LABD vs. BBC
LABD (Direxion Daily S&P Biotech Bear 3x Shares) and BBC (Virtus LifeSci Biotech Clinical Trials ETF) are both exchange-traded funds - LABD is a Leveraged Equities fund tracking the S&P Biotechnology Select Industry Index (-300%), while BBC is a Health & Biotech Equities fund tracking the LifeSci Biotechnology Clinical Trials Index. Both are passively managed. Over the past 10 years, LABD returned -59.09%/yr vs 11.15%/yr for BBC. At a correlation of -0.94, they often move in opposite directions. LABD charges 1.06%/yr vs 0.79%/yr for BBC.
Performance
LABD vs. BBC - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LABD achieves a -53.78% return, which is significantly lower than BBC's 25.75% return. Over the past 10 years, LABD has underperformed BBC with an annualized return of -59.09%, while BBC has yielded a comparatively higher 11.15% annualized return.
LABD
- 1D
- -3.10%
- 1M
- -32.29%
- YTD
- -53.78%
- 6M
- -50.39%
- 1Y
- -87.04%
- 3Y*
- -56.99%
- 5Y*
- -43.25%
- 10Y*
- -59.09%
BBC
- 1D
- 1.59%
- 1M
- 13.54%
- YTD
- 25.75%
- 6M
- 22.73%
- 1Y
- 156.95%
- 3Y*
- 27.00%
- 5Y*
- -0.26%
- 10Y*
- 11.15%
LABD vs. BBC - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
LABD Direxion Daily S&P Biotech Bear 3x Shares | -53.78% | -70.07% | -21.43% | -41.77% | -32.68% | 1.86% | -89.75% | -70.80% | -6.26% | -75.67% |
BBC Virtus LifeSci Biotech Clinical Trials ETF | 25.75% | 63.77% | -1.11% | -1.80% | -35.13% | -22.31% | 30.32% | 63.81% | -18.29% | 57.85% |
Correlation
The correlation between LABD and BBC is -0.92, meaning they tend to move in opposite directions. This is especially valuable for risk management - when one declines, the other has historically tended to hold steady or rise.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.92 |
Correlation (3Y) Calculated over the trailing 3-year period | -0.92 |
Correlation (5Y) Calculated over the trailing 5-year period | -0.94 |
Correlation (10Y) Calculated over the trailing 10-year period | -0.94 |
Correlation (All Time) Calculated using the full available price history since May 28, 2015 | -0.94 |
The correlation between LABD and BBC has been stable across timeframes, ranging from -0.94 to -0.92 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LABD vs. BBC — Risk / Return Rank
LABD
BBC
LABD vs. BBC - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Direxion Daily S&P Biotech Bear 3x Shares (LABD) and Virtus LifeSci Biotech Clinical Trials ETF (BBC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| LABD | BBC | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -5.46 | ||
| Sortino ratioReturn per unit of downside risk | -7.43 | ||
| Omega ratioGain probability vs. loss probability | 0.70 | 1.56 | -0.86 |
| Calmar ratioReturn relative to maximum drawdown | -1.00 | 10.46 | -11.46 |
| Martin ratioReturn relative to average drawdown | -1.37 | 30.65 | -32.02 |
Loading charts...
Drawdowns
LABD vs. BBC - Drawdown Comparison
The maximum LABD drawdown since its inception was -99.99%, which is greater than BBC's maximum drawdown of -76.85%. Use the drawdown chart below to compare losses from any high point for LABD and BBC.
Loading charts...
Drawdown Indicators
| LABD | BBC | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.99% | -76.85% | -23.14% |
Max Drawdown (1Y)Largest decline over 1 year | -86.75% | -15.10% | -71.65% |
Max Drawdown (3Y)Largest decline over 3 years | -96.40% | -54.45% | -41.95% |
Max Drawdown (5Y)Largest decline over 5 years | -98.65% | -71.97% | -26.68% |
Max Drawdown (10Y)Largest decline over 10 years | -99.99% | -76.85% | -23.14% |
Current DrawdownCurrent decline from peak | -99.99% | -19.28% | -80.71% |
Average DrawdownAverage peak-to-trough decline | -90.99% | -37.08% | -53.91% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 64.00% | 5.14% | +58.86% |
Volatility
LABD vs. BBC - Volatility Comparison
Direxion Daily S&P Biotech Bear 3x Shares (LABD) has a higher volatility of 29.98% compared to Virtus LifeSci Biotech Clinical Trials ETF (BBC) at 12.08%. This indicates that LABD's price experiences larger fluctuations and is considered to be riskier than BBC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LABD | BBC | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 29.98% | 12.08% | +17.90% |
Volatility (6M)Calculated over the trailing 6-month period | 65.23% | 26.79% | +38.44% |
Volatility (1Y)Calculated over the trailing 1-year period | 78.79% | 36.27% | +42.52% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 96.66% | 39.52% | +57.14% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 95.97% | 37.75% | +58.22% |
LABD vs. BBC - Expense Ratio Comparison
LABD has a 1.06% expense ratio, which is higher than BBC's 0.79% expense ratio.
Dividends
LABD vs. BBC - Dividend Comparison
LABD's dividend yield for the trailing twelve months is around 9.79%, more than BBC's 1.35% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BBC Virtus LifeSci Biotech Clinical Trials ETF | 1.35% | 1.70% | 1.00% | 0.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.09% | 0.00% | 0.51% |
LABD Direxion Daily S&P Biotech Bear 3x Shares | 9.79% | 6.67% | 4.68% | 6.13% | 0.53% | 0.00% | 3.94% | 1.75% | 0.81% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
LABD and BBC have a correlation of -0.92, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LABD has higher volatility (29.98%) compared to BBC (12.08%). In terms of maximum drawdown, LABD dropped -99.99% vs BBC's -76.85%.
On 10-year performance, BBC leads with 11.15% vs -59.09% for LABD. On fees, BBC is cheaper at 0.79% per year. On volatility, BBC has been the lower-risk option at 12.08%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 10-year period, BBC has performed better with a 11.15% return vs -59.09%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
BBC is cheaper with a 0.79% expense ratio, compared with 1.06% for LABD.
LABD has the higher dividend yield at 9.79%, compared with 1.35% for BBC.
LABD is categorized as Leveraged Equities, while BBC is Health & Biotech Equities. LABD tracks S&P Biotechnology Select Industry Index (-300%), while BBC tracks LifeSci Biotechnology Clinical Trials Index. They also come from different issuers: Direxion and Virtus Investment Partners. Their fees differ too: 1.06% for LABD and 0.79% for BBC.
BBC currently has the higher Sharpe Ratio (4.36 vs -1.11), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for LABD and BBC
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer